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Abstract We developed a 77-item self-reporting ques-
tionnaire to assess the burden of migraine (BURMIG),
including headache characteristics, migraine associated
disability, comorbidities, management, and the conse-
quences on the patients’ lives. We translated BURMIG into
four languages (French, Portuguese, German and English)
and tested it in 130 headache patients (20 pain clinic, 17
primary care and 93 general public) in Luxembourg. We
performed a linguistic and a face-content validation and
tested the questionnaire for its comprehensiveness, internal
consistency and for its retest-reliability at an interval of
1 month (completion rates were 79.6 and 76.4%, for test
and retest, respectively). Retest-reliability for the different
parts of the questionnaire varied between 0.6 and 1.0
(Kappa coefficient), with an intracorrelation coefficient of
0.7–1.0. The internal consistency was between 0.74 and
0.91 (Cronbach’s alpha). The questionnaire BURMIG is
suitable to evaluate the burden of migraine and can be used
in English, German, French and Portuguese.
Keywords Headache  Questionnaire  Burden 
Validation  English  German  French  Portuguese
Introduction
Migraine is a common and disabling neurobiological disor-
der [1] which is under-recognized and under-treated [2, 3]. It
imposes a substantial health burden with nearly all migraine
sufferers experiencing impairment of social activities and of
work capacity [4, 5]. The World Health Report 2002 [3]
ranks migraine as number 12 in women and number 19 in
both genders amongst all causes of disability in the world. In
spite of this, it is estimated that only about 50% of migraine
patients are diagnosed and, therefore, treated adequately
[6–10]. There are a few validated questionnaires such as the
ID migraine to diagnose migraine, and the migraine dis-
ability assessment score (MIDAS) to assess disability in the
last 3 months, but there is no comprehensive questionnaire to
assess migraine associated burden.
The physical and emotional impact of migraine on
individual sufferers, their caretakers, family and colleagues
is poorly acknowledged and this is true as well for the
social and economic burden of migraine on society in
comparison with those of other less prevalent, neurological
disorders [9, 11–13].
We aimed to develop and validate a questionnaire to
assess the burden of migraine after having translated it into
the main languages in order to use it in subsequent studies
in different linguistic populations.
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We designed a questionnaire combining elements from
established questionnaires and added further questions
concerned with disease management and social conse-
quences of headache. Priority areas for the questionnaire
were defined with joint support from NGO’S (Swiss
Migraine Trust Foundation, Migraine Action Association
UK, Switzerland and Luxembourg), several international
headache experts (see ‘‘Acknowledgements’’) and the
Luxembourg Ministry of Health. Ethics committee
approval for the study was obtained from the National
Ethic and Research Board of Luxembourg.
The resulting questionnaire contains 77 items, 17% of
them are open questions. In the first part, the respondents
are asked for biographical details such as age, gender,
their most spoken language and their employment status.
For the purpose of migraine diagnosis, the questions from
‘‘ID migraine’’ [14] are included. Specific information on
headache, such as age of onset, the average number of
headache days per month for the last 3 months, and
symptoms before and after the headaches are gathered as
well as information on general health, and previous and
current disorders using items from the World Health
Organization Disability Assessment Schedule II (WHO-
DAS II) [15], the Migraine Disability Assessment Scale
(MIDAS) [16] and the Patient Health Questionnaire-9
(PHQ-9) [17]. Participants are asked about the influence
of headaches on their job and family-life as well as
whether they ever had consulted medical doctors, about
the diagnosis that was made and about the medication that
had been prescribed. Psychosocial circumstances having
worsened the headaches, limitations in social activities,
conceptions of headache and the need of support from
health professionals to improve the headaches are also
assessed.
Evaluation of the questionnaire
The testing of the questionnaire included face, content,
and language validity; the stability of the questionnaire
over 1 month, a period of time during which little or no
change is expected (Test–retest reliability); the extent to
which the questionnaire is able to discriminate between
respondents with more or less severe disease status
(construct validity) and the extent to which individual
items in a questionnaire correlate with other items
relating to the particular area of investigation (internal
consistency). The respective methodology is detailed
below.
Study population
Patients with headache were recruited from primary care
centres, pain clinics and lay organisations. The idea behind
this recruitment was to test the questionnaire in different
settings. Selection for the primary care setting was done by
doctors in general practice from the personal acquaintance
of the project team. For the pain clinic setting the patients
were selected from the pain clinic of the Centre Hospitalier
de Luxembourg (Central Hospital in Luxembourg). When
consulting because of headaches, both of these patient
groups were asked by their physician to complete the
questionnaire. For a third group of headache patients,
headache sufferers with different employment settings
were consecutively recruited by the national occupational
health service and by a patient organisation.
The samples size needed to investigate internal consis-
tency, construct validity and for test–retest reliability was
estimated by using the kappa formula (see below).
Assuming an absolute precision of 0.18 (given the vali-
dated parts of the questionnaire), we estimated that 73
responses to the main questions in the second test would
enable a Kappa value of C0.5 to be detected with a power
of 0.95 (two-tailed a = 0.05). Thus allowing for a 60%
response rate, 135 subjects were considered necessary.
Face, content and language validity
Initial content validity was explored through systematic
review by experts, and face validity was tested by pre-
piloting with 23 volunteers. All questions which had not
been used before in the respective language in validated
questionnaires were translated using a forward–backward
method with two different native translators. Comprehen-
siveness was piloted with native speaker volunteers.
Test–retest reliability
Questions were categorized by the amount of change
expected, as described previously for the development of a
comparable questionnaire [18], primarily based on the time
frame of the question and blinded to the results as follows:
‘no change expected,’ ‘change unlikely,’ ‘1 unit change
expected,’ ‘3 unit change expected,’ ‘change likely’.
The data from the two periods of answering the ques-
tionnaire were compared to assess test–retest reliability. For
categorical data, this was estimated by using agreement
measures as percentage agreement, Kappa values, Mac Ne-
mar’s S test and Bowker’s S test. Percentage agreement gives
an estimate of within-patient agreement. The Kappa coeffi-
cient indicates when the observed agreement exceeds
chance-agreement; a value above 0.6 is generally considered
as acceptable. The Mac Nemar’s S provide a measure of
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agreement when used between two measures of the same
questionnaire in the same patient. The null hypothesis of the
Bowker’s S test is that the probabilities of cells in the square
table satisfy symmetry. It was used for r 9 c tables where
r [ 2 or c [ 2. For the questions with discrete integer data,
intraclass correlation coefficient (ICC) was calculated using
a 2-way random effects model for agreement.
Construct validity
Comparisons between these samples were made for the
total scores of the WHODASII, MIDAS and PHQ9.
Comparison between categorical scores of the three sam-
ples was performed by using a chi-square test. Continuous
values of the scores were also used for comparison and a
one-way ANOVA was used with the score as dependent
variable. Normality was assessed with a Kolmogorov–
Smirnov test; if significant, data were log-transformed and
analysed if normally distributed. Otherwise, the Kruskall–
Wallis test was used.
Internal consistency/content
Where appropriate, cross-tabulations were used to check
for internal consistency. Blocks of questions corresponding
to ID, WHODASII, MIDAS and PH9 were compared in
terms of correlations.
This was done in order to verify if they measure the
same construct in a multilingual context and in the newly
designed questionnaire. The Cronbach’s alpha coefficient
was used to explore the overall consistency of the ID,
WHODAS II, MIDAS and PHQ-9 questionnaires. The
larger the overall alpha coefficient, the more likely that
items contribute to a reliable scale. A value of 0.70 sug-
gests an acceptable reliability coefficient; smaller
reliability coefficients are seen as inadequate. A coefficient
alpha after deleting each variable independently from the
scale was calculated to determine how each item reflects
the reliability of the scale. When the coefficient increases
after an item is deleted from the scale, one can assume that
the item is not correlated highly with other items in the
scale. Conversely, if the coefficient decreases, it can be
assumed that the item is highly correlated with other items
in the scale.
Results
Population and frequency of headache in the samples
A total of 130 questionnaires were completed leading to a
response rate of 65% (Fig 1). Out of this sample, 15.4%
(n = 20) were from the pain clinic, 13.1% (n = 17) from
the primary care centre and 71.5% (n = 93) from the lay
organisation (Table 1). Fifty-two persons (40%) responded
in German, 1 (0.8%) in English, 72 (55.4%) in French and
5 (3.8%) in Portuguese. Eighty-four percent were women,
mean age was 41.9 ± 11.5, the gender distribution was
significantly different (P = 0.03) between centres. There
was no statistically significant difference in age, age at
onset of headaches, work status and diagnosis of migraine
between the three groups. Headache frequencies were
unequal between centres (P = 0.02) with higher headache
frequencies in subjects at the pain clinic. In the primary
care setting, most individuals were in the 4–9 days/month
category. In the pain clinic, most of the patients had
headache on C15 days/month. The general public popula-
tion had a similar profile as the primary care setting.
Out of 130 subjects of the whole population, 28 did not
answer all the MIDAS questions leading to the unfeasi-
bility to calculation of the total score. Thus, 102 subjects
only had the total score. When re-running the comparison
without the unhealthy subjects, only 10 subjects out the 28
had no total scores. Forty-nine subjects had the total score.
Completion rates
Completion rates for the items of the questionnaire varied
between 5.83 and 100.00%. As the questionnaire included
some questions with more than one possible choice or sub-




























Fig. 1 Tests and samples used in the different steps of the BURMIG
questionnaire validation
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questions with good completion rates. Thus, 63% questions
were found to have completions rates of 90% or more.
Questions where there were several choices tended to have
completion rates around 10%. There was no difference for
completion rates between genders and language groups.
Completion rates of the second questionnaire varied from
5.41 to 100% and were very similar to the first question-
naire (63% of questions with completion C90%).
Test–retest reliability
Out of the 130 subjects recruited for the validation process,
91 subjects replied a second time to the questionnaire sent
1 month later. Seventy-nine single items (including sub-
questions) were used to assess reliability, excluding open
questions; 67.1% of the items (n = 53) were over an 80%
agreement, whereas 13.9% (n = 11) ranged between 60
and 80% and 19% (n = 15) were below a 60% agreement.
The Kappa coefficient ranged from 0.23 to 0.99. Ques-
tions categorized as ‘no change expected’ (0.86–0.99) and
‘change unlikely’ (0.68–0.99) showed a good agreement
(Table 2). From the items categorized as ‘1 unit change
expected’ or ‘3 unit change expected’ the kappa showed
values ranging from 0.45 to 0.92, indicating a poor
agreement for some questions; unsurprisingly, from the
items categorized as ‘change likely’ the kappa value
showed lower values ranging from 0.23 to 0.77. Questions,
which showed the smallest agreement, were the items from
the WHODAS II, PHQ9 and questions 5 and 6 from the
MIDAS.
Mac Nemar’s S test showed no significant differences.
Only one item was significant (P = 0.03) with the Bow-
ker’s S test: No agreement was observed for ‘Feeling tired
or having little energy’ from the question 25 (PHQ9)
between the two measures. The intra-class correlation
coefficient for quantitative answers is detailed in Table 2.
Values were significant for questions 15 (from WHODAS
II) and 18 (from MIDAS) (Table 3).
Construct validity
The mean frequency of headache days was significantly
different between the three samples (Table 5). While few
subjects had high headache frequency in the primary care
and general population samples, a large proportion (45% of
subjects) in the pain clinic sample had C15 headache days
per month. However, there was no difference between the
three samples in terms of average disability attributed to
headaches (MIDAS total score) or of depression (as mea-
sured by PHQ9). The mean scores of WHODASII, MIDAS
and PHQ9 were not different between the three samples
(Table 6) except for a significant pair-wise difference
between the pain clinic and the general population sample
with the MIDAS total score (P \ 0.05) (Table 4).
A subanalysis was carried-out after omitting patients
(n = 71) with headache from the general population
Table 1 Socio-demographic and headache characteristics of the validation sample
Primary care Pain clinic General public All P value
Age Year (mean ± SD) 38 ± 13 39 ± 10 43 ± 11 41 ± 11 0.14
Gender M/F (%) 0/100 30/70 16/84 16/84 0.03
Work status Economic workers (%) 70 75 73 73 0.95
Diagnosis Migraine days/month (%) 88 70 76 77 0.45
Headache frequency \1 (%) 0 0 2 2
1–3 (%) 29 30 21 24
4–9 (%) 35 10 45 38
10–14 (%) 18 15 19 18
[15 (%) 18 45 12 18 0.02
Age of onset Year (mean ± SD) 24 ± 10 20 ± 11 20 ± 10 20 ± 10 0.36






No change expected 79.12–98.90 0.86–0.99 \0.0001
Change unlikely 79.12–98.90 0.68–0.99 \0.0001
±1 unit change expected 90.11–96.70 0.45–0.92 \0.0001
±3 unit change expected 72.53–84.62 0.45 \0.0001
Change likely 54.95–89.01 0.23–0.77 \0.0001
Table 3 Test–retest reliability with McNemar’s coefficient for 2 9 2
tables, Bowker’s coefficient for more than 2 classes variables and
intraclass correlation for continuous variables
Statistic P value
McNemar’s coefficient 0.11–3.57 0.74–0.06
Bowker’s coefficient 0.00–10.07 0.03–1.00
Intraclass correlation 0.79–0.99 0.04–0.92
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sample in order to better discriminate WHODASII,
MIDAS and PHQ9 values between levels of headaches.
The remaining general population sample (n = 22) was
assumed completely healthy while the pain clinic sample
was supposed to be the most affected group. Results
showed a clear trend (P = 0.06) for the mean number of
days with headaches and the presence of depressive dis-
order (P = 0.09). A highly significant difference was
observed between the general population sample, the pain
clinic and the primary care sample for MIDAS scores (P
value = 0.0005) but not for the PHQ9 depressive disorder
estimate (Table 5).
The mean WHODASII score did not show any signifi-
cant difference in this subanalysis while for MIDAS and
PHQ9, total scores were significantly different (Table 6).
When further analysing pair-wise relationships between
the three samples, differences (P \ 0.05) were observed
between the MIDAS score of the pain clinic sample and the
general population sample when including all subjects, and
also between the PHQ9 scores of the primary care and the
general population sample (Table 6) when excluding
incompletely healthy subjects from the general population
sample.
Internal consistency/content
The standardized values of the Cronbach’s alpha to test the
consistency of (ID, WHODASII, MIDAS and PH9 tested in
the new questionnaire were 0.26, 0.91, 0.74 and 0.84,
respectively. Questions categorized by the amount of
change expected and compared between the test and the
retest time to assess the internal consistency showed a 80–
100% agreement except for open questions where more
than 70% change was observed (Electronic supplementary
material).
Discussion
We described the development and methodological testing
of a self-reporting questionnaire to evaluate the burden of
migraine in the general population.
Completion rates for each question were generally good
with the vast majority between 60 and 90%. A small number
Table 4 Internal consistency
Raw Standardized
ID Migraine ScreenerTM 0.26 0.26
WHODAS II questionnaire 0.80 0.91
MIDAS questionnaire 0.68 0.74
PHQ-9 questionnaire 0.85 0.84
Table 5 Construct validity for frequency of headaches, MIDAS, and PH9 categorical scores













N mean (days/month of headaches)
Less than 1 day 0 (0%) 0 (0%) 2 (2.15%) 2 1 (4.55%) 1
1–3 days 5 (29.41%) 6 (30%) 20 (21.51%) 31 7 (31.82%) 18
4–9 days 6 (35.29%) 2 (10%) 42 (45.16%) 50 9 (40.91%) 17
10–14 days 3 (17.65%) 3 (15%) 18 (19.35%) 24 4 (18.18%) 10
[15 days 3 (17.65%) 9 (45%) 11 (11.83%) 23 1 (4.55%) 13
Total 17 (13.08%) 20 (15.38%) 93 (71.54%) 130 0.0238 22 (37.29%) 59 0.0629
MIDAS score
Minimal or infrequent disability 3 (23.08%) 4 (23.53%) 14 (19.44%) 21 9 (47.37%) 16
Mild or infrequent disability 0 (0%) 0 (0%) 10 (13.89%) 10 5 (26.32%) 5
Moderate disability 6 (46.15%) 2 (11.76%) 18 (25%) 26 4 (21.05%) 12
Severe disability 4 (30.77%) 11 (64.71%) 30 (41.67%) 45 1 (5.26%) 16
Total 13 (12.75%) 17 (16.67%) 72 (70.59%) 102 0.159 19 (38.78%) 49 0.0005
Depressive disorder
No 14 (82.35%) 17 (85%) 86 (92.47%) 117 22 (100%) 53
Yes 3 (17.65%) 3 (15%) 7 (7.53%) 13 0 (0%) 6
Total 17 (13.08%) 20 (15.38%) 93 (71.54%) 130 0.3179 22 (37.29%) 59 0.0977
Headache days, the MIDAS score as a measure of disability and the presence of depression are detailed for the different samples of participants
according to their origin. On the right hand side of the table, the subset of healthy participants (without headache) in the generation population
sample, is detailed
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of questions showed low completion rates which can be
explained by the fact that they were part of multiple-choice
questions. Some other questions did not have to be answered
in all participants since they applied only to subgroups.
Questions from WHODAS II and PHQ9 showed both, good
completion rates, and good reliability. For methodological
purposes, we had defined the amount of change expected for
each question before administering the questionnaire.
Questions, where a change had been expected, actually
showed higher amounts of change and lower reliability. This
means, that these items were used in an appropriate way and
that they can be used as part of a questionnaire on the impact
and burden of migraine and headaches. The question
‘‘Feeling tired or having little energy’’ from PHQ9 was found
to have little re-test reliability at 1 month interval which can
be explained by the transient character of this item.
Internal consistency was evaluated independently for
each scale tested within in the questionnaire. It was found
to be excellent for the MIDAS and somewhat smaller for
questions from WHODASII and PHQ9.
Construct validity was found to be acceptable when
samples were adequately chosen to discriminate between
levels of headache. However, questions from WHODAS
showed a poor discrimination between headache patients
and the general population. This can be explained by the
fact that this tool is not specifically designed for headache
sufferers. The headache specific MIDAS, as expected,
showed good discriminative power.
Disease management
Regarding questions on disease management, agreement
ranged from 77 to 98% (except for multiple-choice
questions). Kappa coefficient ranged from 0.68 (0.62 with
multiple-choice questions) to 1.00 which indicates good
agreement between the two steps.
The majority of the questions about private and social
influence were of the multiple-choice type and scored
poorly in terms of percentage agreement (10–30%), but had
a good retest reliability (kappa coefficients ranging from
0.52 to 0.97). These questions were therefore stable with
time and could be used in a large study with a period of
recruitment lasting a few months.
Changes brought to the final questionnaire
In the disease management part, two questions on medical
doctor consultations were merged into one question
allowing a better completion.
In one question on the temporal relation between
headache and other problems, in addition to ‘‘before,’’ and
‘‘after’’ a third item ‘‘during’’ was added.
Conclusions
A new questionnaire, BURMIG, was developed with the
aim to estimate the burden of migraine. It uses established
and previously validated items for diagnosis and to
measure disability and depression. Questions related to
disease management and the influence on daily living
were added. The resulting questionnaire was tested in a
sample in the Grand Duchy of Luxembourg. Reliability
and consistency of BURMIG were found to be compa-
rable to previously published questionnaires. Therefore,
this tool is suitable to study larger populations of head-
ache patients.
Table 6 Pairwise differences of WHODASII, MIDAS and PH9 scores between groups
General population sample Without unhealthy subjects
N Mean SD P value N Mean SD P value
WHODAS-II score12
Primary care 13 25.85 15.15 0.5752 13 25.85 15.2 0.3015
Pain clinic 15 21.3 18.42 15 21.3 18.4
General population sample 84 24.14 15.09 21 17.59 12.8
MIDAS score
Primary care 13 22.92 22.73 0.2588* 13 22.92 22.7 0.0039*
Pain clinic 17 38.47 33.87 17 38.47 33.9
General population sample 72 22.71 20.84 19 7.37 7.11
Score PHQ-9
Primary care 17 9.24 4.51 0.219 17 9.24 4.51 0.0049**
Pain clinic 20 8.1 5.62 20 8.1 5.62
General population sample 93 7.53 4.59 22 4.95 2.57
* Significant pairwise difference between pain clinic and general pop at the 5% level (Tukey post-hoc ANOVA tests)
** Significant pairwise difference between primary care and general pop at the 5% level (Tukey post-hoc ANOVA tests)
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